Targovax is Invited to Present at Upcoming 2018 Investor and Industry Conferences

OSLO, Norway, Nov. 28, 2018 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences:

Date: 29 November 2018  

Venue: Nordic-American Life Science Conference, NYC, US

Keynote panel: The Allure and Challenges of Nordic Healthcare Acquisitions and Partnerships

Time: 12:30 PM EST

Time: 3:00 PM EST           
Presenter: Torbjørn Furuseth, CFO

Date: 5 December 2018

Venue: 4th Annual Oncolytic Virotherapy Summit, Boston, USA

Time: 12:30 PM EST
Presenter: Erik Digman Wiklund, CBO

Panel Discussion: Comparing and Contrasting Virus Types

Time: 4:30 PM EST

The 4th Oncolytic Virotherapy Summit is the leading international conference in the oncolytic virotherapy field for biotech and pharma drug developers to gain scientific and clinical trial updates. In the above mentioned panel discussion, Erik Digman Wiklund, CBO of Targovax, will, together with William Jia, CSO of Virogin, Robert Coffin, CEO of Replimune and Stephen Russell, CEO of Vyriad discuss wild-type and newer generations viruses expressing immune stimulatory payloads or tumor antigens.

The presentations will be available to download at www.targovax.com following these events.

For further information, please contact:

Renate Birkeli, Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com 

Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no

Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44-20-3727-1000
Email: Targovax@fticonsulting.com

This information was brought to you by Cision http://news.cision.com


Cision View original content:http://www.prnewswire.com/news-releases/targovax-is-invited-to-present-at-upcoming-investor-and-industry-conferences-300756622.html

SOURCE Targovax

Company Codes: Bloomberg:TRVX@NO, ISIN:NO0010689326, LSE:0RIS, Oslo:TRVX, RICS:TRVX.OL, Stockholm:TRVXO  

Back to news